Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.55 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.45 |
| ▸ | SCN2B | O60939 | 2/20 | 0.45 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118985 | 0.81 | HDAC8 (0.58) | KAT6ASCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL20178561 | 0.81 | KAT6A (0.58) | SMYD3KAT6ASCN9AHDAC8HDAC6 | |
| SCHEMBL15601953 | 0.79 | KAT6A (0.46) | SMYD3KAT6ABRAF | |
| SCHEMBL20178589 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL30436806 | 0.78 | SCN2B (0.58) | KAT6ASCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL20173758 | 0.78 | KAT6A (0.52) | KAT6ASCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL20178559 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL20178601 | 0.77 | KAT6A (0.54) | SMYD3KAT6ASCN9ASMN1; SMN2HDAC8 | |
| SCHEMBL12142424 | 0.77 | HDAC6 (0.59) | SMYD3KAT6AHDAC8HDAC6 | |
| SCHEMBL3808268 | 0.77 | HDAC3 (0.50) | KAT6ASCN9ASCN5AHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | SMYD3 3843/4885KAT6A 2864/4885SCN9A 2939/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | SMYD3 3843/4885KAT6A 2864/4885SCN9A 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.